Vistagen Therapeutics Inc.

Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen’s pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. Its portfolio includes PH94B, a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia. PH10, an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.

Address: 343 Allerton Avenue,South San Francisco South San Francisco South San Francisco CA 94080 US
Phone: +1 650 577-3600
Email: [email protected]

In The Press

Vistagen Therapeutics Inc. News

Dec 16, 2022

KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing

Read More
Dec 13, 2022

KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th

Read More
Aug 31, 2020

(LD Micro) 360 Companies Set to Present - this Week

Read More
Aug 05, 2020

LD Micro Announces Preliminary List of Presenters for the LD-500

Read More
Aug 13, 2019

VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results

Read More
Jul 23, 2019

VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray

Read More
Jun 25, 2019

VistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline Overview

Read More
Jun 20, 2019

VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease, Without The Psychological Side Effects And Safety Concerns Of Amantadine

Read More